We provide a number of genetically-modified animal models including gene humanized models, KO models, immunodeficient models, aged mice, tool mice and humanized cell lines for basic and preclinical research.
on this page
Developing a new drug for human use is a lengthy and costly process that takes an average of 10 years or more and costs approximately $2.6 billion. Yet, when one considers the number of people a successful drug can help, the return on investment can be astounding.
Before a drug goes to market, its efficacy, safety, and mechanism of action (MOA) must be thoroughly understood. Animal models for research work to minimize adverse side effects and maximize therapeutic properties of a drug before it is taken to clinical trials. Biocytogen is a one-stop CRO that provides humanized mouse models for immuno-oncology and autoimmune/inflammatory disease targets, which can help move projects from target to IND application.
Animal models are benefit tools for basic research and drug development. . Leveraging our advanced gene editing technologies, Biocytogen developed over 3,300 animal and cell models including humanized mouse models, immunodeficient mice & rats and its second generation models, other mouse models and humanized cell lines. Our innovative models are at the forefront of advancing research and accelerating the development of new treatments.
Biocytogen utilizing advanced gene-editing technologies to modify specific gene loci in mice while keeping other genes and physiological systems unchanged. This approach allows for precise investigation into the functions of specific human genes and their roles in diseases. The related animal models cover areas such as oncology, autoimmune diseases, metabolism, and neurology. Leveraging their extensive experience in animal model development, they design detailed and scientifically rigorous strategies by carefully considering all factors that could potentially influence gene expression. This ensures the stability and reliability of gene expression, significantly enhancing the stability of the models.
See DetailsSince our inception in 2009, our company's strong focus on genetic engineering has led to the creation of multiple strains of mice for preclinical efficacy testing as well as antibody drug discovery. More recently, our team has been working to create knockout mice for key drug target genes to facilitate mechanistic studies and target discovery. For this purpose, we are pleased to introduce more than 800 new strains of knockout mice, now available to the global biomedical research community.
See DetailsAged mice serve as an effective model for studying human aging in drug development. They replicate key physiological characteristics of the elderly, such as organ function decline and weakened immune responses, and they closely mirror human pathologies like Alzheimer's disease, osteoporosis, and tumor microenvironment changes. This model allows researchers to investigate how aging affects drug dynamics—from absorption and metabolism to target interactions. Consequently, aged mice play a crucial role in bridging laboratory discoveries with clinical applications in translational medicine.
See DetailsBiocytogen has developed various Cre mice and DTR mice with expression in specific tissue and specific cell. Additionally, Biocytogen have developed reporter mice, which allow us to observe gene expression at the tissue or cellular level through experimental instruments when the reporter gene is expressed. This facilitates in vivo gene expression monitoring, cell labeling, and lineage tracing studies.
See DetailsBiocytogen, with over a decade of engineering experience, has successfully modified a variety of cell lines. The company integrates gene editing technologies such as EGE, ES, and has developed humanized cell lines targeting immune checkpoints (e.g., PD-L1), tumor-specific antigens (e.g., HER2, TROP2), and other immune cell-associated cell lines. These cell lines are relevant to colon cancer, melanoma, hepatocellular carcinoma, breast cancer, and other solid tumors. These achievements have significantly improved the efficiency of research and development in tumor immunotherapy, monoclonal antibody, bispecific antibody, polyclonal antibody, tumor vaccine, and ADC drug optimization, establishing Biocytogen as a key tool for preclinical research.
See DetailsDue to species limitations, wild-type mice are typically unable to evaluate human-specific drugs effectively. At Biocytogen, we developed drug target humanized mouse models by incorporating and replacing mouse genes with human ones allow drug candidates to bind with humanized targets, enabling critical in vivo evaluations of drug efficacy, toxicity, and accurate pharmacokinetics/pharmacodynamics (PK/PD).
Targets of our humanized mouse models cover immune-checkpoint, tumor microenvironment (TME) modulators and tumor-associated antigens (TAA) for oncology research，cytokines/cytokine receptors and other biomarkers related to autoimmune and inflammatory diseases, as well as metabolic and neurological disorders.
Using the advanced gene editing platform, our experts team professionally designs the genetic modifications in target humanized mice. These genetically humanized mice exhibit expression profiles similar to humans, ensuring that humanized genes do not interfere with the mice's signaling pathways or functions.
Our animal models have comprehensive validation data, including genotypic and phenotypic analysis, functional assays and in vivo studies.
Supported by a high-quality animal center, we provide large-scale breeding services that minimize variation among individual mice and experimental batches. This ensures consistency and reliability in preclinical studies, contributing to more robust and reproducible research outcomes.
Our animal models are independently developed and fully owned by us, holding independent intellectual property rights, which provide clients with reliable and secure research tools that ensure the integrity and reproducibility of experimental data.
Biocytogen has been serving customers around the world, both in academia and industry, for over a decade. With our commitment to quality in everything we do, we'll work closely with you to deliver models and services that meet your precise specifications in a timely manner. We offer world-leading, cutting-edge technology platforms, superior service, a fast timeline, a large collection of animal models for research and a 100 percent satisfaction guarantee.
We have established a world-class animal model production center, including three animal faculties encompassing a total of approximately 55,000 sq. m., with an annual supply capacity of 800,000 gene-edited mice. Shipping is available to our customers worldwide.
For more information about our products and services, contact us today.
